Plus Therapeutics

Along with the excitement around the rebrand to and ticker change CNSY, our latest press release included several more key updates:

- Year-to-date, 232 tumor cell enumeration tests have been performed, and are on track to achieve a run rate of 1,250 tests per annum by the end of 2026

- June was the highest volume month on record, with 72 CNSide Diagnostics' tests performed

- Based on the growth in test requisitions, Plus expects to achieve a run rate of 1,250 tests per annum by the end of 2026

- 18 institutions are onboarded and ordering

- 17 additional institutions are in process and approximately 70 individual end-user portal agreements have been signed by healthcare providers and their staffs

Check out the full press release to stay updated on the company’s latest key milestones and positive CNSide Diagnostics commercial progress: https://bit.ly/4vz4OPn

Today we’re featuring ' VP of Development and Technical Operations, Daniel Ortega!

Daniel leads our end-to-end drug development across the company’s portfolio, including: GMP manufacturing, clinical supply chain management, and CMC oversight. He brings two decades of pharmaceutical industry experience, including technical and leadership roles at Azaya Therapeutics, Mission Pharmacal, and Viatris.

Learn more about our leadership team: https://bit.ly/4slXmpE

announces that it has signed a national agreement with Elevance Health, Inc., effective May 1, 2026, covering approximately 45.4 million people throughout the United States, to provide the Cerebrospinal Fluid (CSF) Tumor Cell Enumeration (TCE) assay.

This brings CNSide Diagnostics' CSF TCE assay total coverage to 126 million people.

Full press release here: https://bit.ly/4oKAD5c

' President and CEO, Dr. Marc Hedrick, recently joined the Rare Connection podcast to discuss emerging approaches to diagnosing and treating cancers affecting the central nervous system, including (LM), recurrent ( ), and pediatric brain cancers.

Dr. Hedrick also covers the CNSide Diagnostics' platform, how cerebrospinal fluid is analyzed to identify cancer cells, and how targeted are being investigated in ongoing .

Check out the podcast here:

Targeting Brain Tumors: The New Radiotherapeutic Trial You Need to Know What happens when cancer spreads to the fluid surrounding the brain...